Molecular Signature to Risk-Stratify Prostate Cancer of Intermediate Risk.
A new 30-gene signature has been described that separates prostate cancers of Gleason score ≤6 from those of Gleason score ≥8. It provides independent prognostic information for prostate cancers of intermediate risk (Gleason score of 7), which has the potential to stratify these patients into different risk groups. Clin Cancer Res; 23(1); 6-8. ©2016 AACRSee related article by Sinnott et al., p. 81.
Department of Pathology, Anhui Medical University, Hefei, China.|Department of Pathology, Duke University School of Medicine, Durham, North Carolina.
Yu
Y
Yin
Department of Pathology, Duke University School of Medicine, Durham, North Carolina.|Department of Pathology, the First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, China.
Qingfu
Q
Zhang
Department of Pathology, Duke University School of Medicine, Durham, North Carolina.
Hong
H
Zhang
Department of Pathology, Duke University School of Medicine, Durham, North Carolina.
Yiping
Y
He
Department of Pathology, Duke University School of Medicine, Durham, North Carolina. Jiaoti.huang@duke.edu.
Jiaoti
J
Huang
D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D060787:Neoplasm Grading; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D059467:Transcriptome